Lenti-LHR CAR (scFv-28BBζ, 2H11-37)-VP (VP-CAR-LC720)

The ready-to-use lentiviral particles of Lenti-LHR CAR (scFv-28BBζ, 2H11-37)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (2H11-37)-CD28-41BB-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.


  • Type of Therapeutics
  • Chimeric Antigen Receptor
  • Target
  • LHR
  • Expression Cassette
  • scFv (2H11-37)-CD28-41BB-CD3ζ
  • Clone
  • 2H11-37
  • Promotor
  • EF1a
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Ovarian Cancer


  • Introduction
  • This gene encodes the receptor for both luteinizing hormone and choriogonadotropin. This receptor belongs to the G-protein coupled receptor 1 family, and its activity is mediated by G proteins which activate adenylate cyclase. Mutations in this gene result in disorders of male secondary sexual character development, including familial male precocious puberty, also known as testotoxicosis, hypogonadotropic hypogonadism, Leydig cell adenoma with precocious puberty, and male pseudohermaphtoditism with Leydig cell hypoplasia.
  • Alternative Names
  • LHCGR; luteinizing hormone/choriogonadotropin receptor; HHG; LHR; LCGR; LGR2; ULG5; LHRHR; LSH-R; LH/CGR; LH/CG-R

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.